Explore

New Research Reveals Distinct Tau Pathology in Early-Onset Alzheimer's, Suggesting Tailored Treatment Approaches

New Research Reveals Distinct Tau Pathology in Early-Onset Alzheimer's, Suggesting Tailored Treatment Approaches

A new study has revealed that early-onset Alzheimer's disease, which affects individuals under 65, exhibits a distinct and more aggressive tau pathology compared to late-onset Alzheimer's. Researchers compared 390 early-onset patients (average age 59) with 211 late-onset patients (average age 78), all with mild cognitive impairment or mild dementia and confirmed amyloid positivity. The study found that early-onset patients had higher initial levels of tau, spread across more brain regions, and accumulated tau twice as fast. This aggressive tau accumulation was more strongly linked to memory loss progression in younger patients. The findings suggest that early-onset Alzheimer's is not merely an earlier manifestation of the late-onset form but a distinct disease process, often presenting with non-memory-dominant symptoms like difficulties with language, vision, or executive functions.

New Scoring System Developed to Identify Hidden Sleep Issues in Advanced Parkinson's Disease Patients

New Scoring System Developed to Identify Hidden Sleep Issues in Advanced Parkinson's Disease Patients

A new sleep scoring system has been developed to better track sleep disruptions in individuals with advanced Parkinson's disease, according to a study published in Sleep Medicine. Standard monitoring methods often fail to detect unique disruptions in brain activity caused by the disease. Researchers identified five new stages of abnormal sleep and wakefulness that are not present in healthy individuals or those in the early stages of Parkinson's. These disturbances are closely linked to older age, cognitive decline, and fluctuating motor symptoms. The study involved 15 adults with Parkinson's and five age-matched healthy controls. Overnight video-polysomnography was used to record brain waves, eye movements, muscle activity, and breathing. The new method detected these abnormal sleep stages in 12 out of 15 Parkinson's patients, accounting for a significant portion of their recording time. The three remaining patients, who were in early stages without cognitive impairment or motor fluctuations, could be ful...

Feinstein Institutes Awarded $3.4M NIH Grant for AI-Powered Delirium Detection in Hospitals

Feinstein Institutes Awarded $3.4M NIH Grant for AI-Powered Delirium Detection in Hospitals

Researchers at Northwell Health’s Feinstein Institutes for Medical Research have received a $3.4 million grant from the National Institutes of Health (NIH). This funding will support the development of advanced artificial intelligence (AI) tools aimed at detecting and preventing delirium in hospital settings, particularly among older patients. Delirium, a serious medical condition characterized by acute mental disturbance, is a significant risk factor for Alzheimer’s disease and related dementias (AD/ADRD). It often affects individuals over 65 during hospitalization and is frequently missed by clinicians in over 75% of cases, even with screening programs. The project, led by Dr. Liron Sinvani, Dr. Alex Makhnevich, and Dr. Theodoros P. Zanos, will create machine learning AI models to identify delirium in the emergency department (ED) and predict its onset during hospitalization. These models will utilize electronic health record data and continuous monitoring from wearable devices, with validation across di...

High-Dose Flu Shots for Seniors: CDC Preference and Alzheimer's Risk Research

High-Dose Flu Shots for Seniors: CDC Preference and Alzheimer's Risk Research

The Centers for Disease Control and Prevention (CDC) has recommended high-dose, recombinant, or adjuvanted flu vaccines for adults aged 65 and older since the 2022-23 season. This preference is based on randomized trials demonstrating that these enhanced shots reduce lab-confirmed flu and flu-related hospitalizations by approximately 25% to 33% or more compared to standard doses. While these high-dose vaccines may cause slightly more mild side effects like sore arms or headaches, serious adverse events are not significantly more common. Separately, a new observational study published in Neurology by a UTHealth Houston group explored a potential link between high-dose flu shots and a lower risk of Alzheimer's dementia in this age group, though this finding is still under scrutiny due to methodological limitations.

Cleveland Clinic Study Reveals Gene-Silencing Therapy's Dual Impact on High Cholesterol and Triglycerides

Cleveland Clinic Study Reveals Gene-Silencing Therapy's Dual Impact on High Cholesterol and Triglycerides

A new study led by Cleveland Clinic has demonstrated that a single dose of ARO-DIMER-PA, a gene-silencing medication, significantly reduced both 'bad' cholesterol (LDL-C) and triglycerides in patients diagnosed with mixed hyperlipidemia. The findings were presented at the American Heart Association’s Scientific Sessions 2026 in Chicago. Dr. Luke Laffin, study author and medical director of the Cleveland Clinic Coordinating Center for Clinical Research, highlighted that this is the first time a single drug has successfully blocked two separate disease pathways in the liver simultaneously. The medication, a small interfering RNA (siRNA), targets and silences both APOC3 and PCSK9 genes, which are involved in lipid metabolism. While other siRNA medications typically target only one gene, ARO-DIMER-PA's dual action led to dose-dependent reductions in PCSK9 and APOC3 proteins by 50-89% and 43-95% respectively. Consequently, LDL-C was reduced by 26-65% and triglycerides by 56-78%. The drug was generally well-tole...

VA Research Highlights Brain Health Interventions for Aging and Huntington's Disease

VA Research Highlights Brain Health Interventions for Aging and Huntington's Disease

Recent research from the Department of Veterans Affairs (VA) has unveiled promising findings regarding brain health, focusing on interventions for healthy brain aging and managing Huntington's disease. A VA Kansas City study indicated that supplementation with nicotinamide riboside, a form of vitamin B3, could promote healthy brain aging and reduce cognitive decline. In a mouse model, this supplement improved memory and learning, reduced inflammation in brain immune cells, and increased gene activation related to learning and memory. Separately, VA Portland researchers conducted a pilot study on time-restricted eating for individuals with Huntington's disease. Twenty participants limited their eating to a six-to-eight-hour window daily for 12 weeks. The intervention was well-tolerated, with participants showing improvements in disease severity scores and a 13% average decline in blood biomarkers of nerve cell damage. These findings suggest that time-restricted eating could potentially slow the progression ...

Brain Health Research Shifts Focus to Nutrient Absorption and Personalized Nutrition

Brain Health Research Shifts Focus to Nutrient Absorption and Personalized Nutrition

The field of brain health research is evolving beyond simply identifying beneficial nutrients to understanding how these nutrients are absorbed, transported, and utilized by the brain. Scientists are now investigating the complex processes of nutrient delivery, such as how docosahexaenoic acid (DHA), a crucial omega-3 fatty acid, crosses the blood-brain barrier. A landmark study published in Nature identified a transporter called MFSD2A, which facilitates DHA movement into the brain when attached to lysophosphatidylcholine (LPC). This discovery highlights that the molecular form of a nutrient can significantly influence its brain accessibility. Additionally, there is a growing interest in personalized nutrition, recognizing that individual differences in age, health status, and metabolism may require tailored dietary recommendations rather than generalized approaches. This shift aims to provide a more detailed understanding of the relationship between nutrition and brain function.

New Dementia Study Links Estrogen Exposure to Better Brain Health in Women

New Dementia Study Links Estrogen Exposure to Better Brain Health in Women

A new study published in Neurology has suggested a link between estrogen exposure and healthier brain vessels, potentially impacting brain health in women. The research, involving 352 women with a mean age of 70, found that women with a longer reproductive lifespan—meaning a longer period of natural estrogen exposure from their first period to menopause—tended to show fewer signs of damage to the brain's small blood vessels. Additionally, women who had used estrogen-based oral contraceptives or menopausal hormone therapy (MHT) were more likely to exhibit signs of improved brain health, including stronger connections between different brain regions and, for MHT users, fewer signs of small blood vessel damage. Alzheimer's Research UK acknowledged these findings as 'interesting' but emphasized that, as an observational study, it cannot prove cause and effect, and more research is needed.

Novartis-Sponsored Drug Pelacarsen Fails to Prevent Heart Attacks and Strokes in Crucial Study

Novartis-Sponsored Drug Pelacarsen Fails to Prevent Heart Attacks and Strokes in Crucial Study

An experimental drug, pelacarsen, designed to reduce levels of lipoprotein(a) (Lp(a)) in the blood, unexpectedly failed to prevent heart attacks and strokes in a major study. The research, led by cardiologist Steven Nissen of the Cleveland Clinic, involved 8,350 adults with existing heart disease who were given either pelacarsen or a placebo. While the drug successfully suppressed Lp(a) levels by approximately 78%, this reduction did not translate into a decrease in cardiovascular complications over a five-year period. The findings were presented at an American Heart Association meeting in Chicago and published in the New England Journal of Medicine and NEJM Evidence. Drugmaker Novartis, which sponsored the study, had previously announced the study did not meet its goals without releasing specific details, stating only that it provided 'meaningful evidence' about the relationship between Lp(a) and heart disease.

Cleveland Clinic Trial Reveals Novel Drug Ineffective in Reducing Cardiovascular Events

Cleveland Clinic Trial Reveals Novel Drug Ineffective in Reducing Cardiovascular Events

A significant clinical trial led by Cleveland Clinic has concluded that pelacarsen, a drug designed to lower lipoprotein(a) (Lp(a)), did not reduce major adverse cardiovascular events over a 4.7-year follow-up period. The Phase 3 Lp(a)HORIZON trial involved 8,322 patients across 797 sites in 42 countries, all of whom had existing heart disease and elevated Lp(a) levels, and were already receiving standard treatments. Patients were randomly assigned to receive either 80 mg of pelacarsen or a placebo via monthly self-administered injections. The primary endpoint, defined as the time until a patient's first major cardiovascular event (heart-related death, heart attack, stroke, or urgent heart procedure), occurred in 12.3% of the pelacarsen group and 12.1% of the placebo group. While pelacarsen effectively lowered Lp(a) levels by 78.4% after one year compared to a 3.2% reduction in the placebo group, this significant reduction did not translate into a decrease in cardiovascular events. The drug also presented ...

University of Texas at Dallas Research Challenges Cognitive Decline, Shows Brain Health Improvement Across Adulthood

University of Texas at Dallas Research Challenges Cognitive Decline, Shows Brain Health Improvement Across Adulthood

Lori Cook, Director of Clinical Research at the Center for BrainHealth at the University of Texas at Dallas, has presented new research challenging the long-held belief that cognitive decline is an inevitable part of aging. Her team followed nearly 4,000 adults, aged 19 to 94, over a three-year period. The study found that brain health can improve across adulthood, rather than merely being protected from decline. Participants engaged in online interventions that included brain strategy training, lifestyle tips, personalized coaching, and ongoing performance tracking using the BrainHealth Index™. This index measures clarity of thinking, emotional balance, and a sense of connectedness. The research indicated that both young and older adults showed improvements, with those starting with lower brain health often making the most significant gains. Crucially, the study highlighted that these improvements were not passive, with the greatest gains observed in individuals who consistently adopted brain-healthy habi...

National Multiple Sclerosis Society Funds New Initiative for Earlier MS Detection

National Multiple Sclerosis Society Funds New Initiative for Earlier MS Detection

The National Multiple Sclerosis Society has launched a new funding opportunity aimed at accelerating the early detection of multiple sclerosis (MS). This initiative seeks to support the creation and validation of screening methods that are scalable, practical for clinical use, and cost-effective. The goal is to identify individuals who require comprehensive neurological evaluations across various healthcare settings. Currently, diagnosing MS involves magnetic resonance imaging (MRI), clinical assessments, and the McDonald diagnostic criteria. However, MS lacks a single definitive diagnostic test, and its symptoms can overlap with other conditions, necessitating thorough evaluation. The Society's new funding aims to overcome these diagnostic challenges by fostering innovative approaches to identify MS earlier.